HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heartfailure with mildly reduced or preserved ejection fraction and systemic inflammation. - HERMES_EX6018-4915
A 26-week, randomised, multicentre, open-label, active-controlled, parallel group, two armed,treat-to-target trial investigating the effect on glycaemic control and safety of treatment with onceweekly Insulin Icodec compared to once daily Insulin Degludec, both in combination with InsulinAspart in adults with type 1 Diabetes, with a 26-week extension investigating long term safety. - ONWARDS 6
A research study to compare two types of insulin, a new weekly insulin, insulin icodec and an available daily insulin, insulin glargine, both in combination with mealtime insulin, in people with type 2 diabetes who use daily insulin and mealtime insulin. - ONWARDS 4
100 项与 Novo Nordisk India Pvt Ltd. 相关的临床结果
0 项与 Novo Nordisk India Pvt Ltd. 相关的专利(医药)
100 项与 Novo Nordisk India Pvt Ltd. 相关的药物交易
100 项与 Novo Nordisk India Pvt Ltd. 相关的转化医学